Investing.com - Financial Markets Worldwide
Get 50% Off
🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

Pacific trade deal adds to U.S. price quandary for biotech drugs

Published 2015-10-05, 04:51 p/m
© Reuters. Pacific trade deal adds to U.S. price quandary for biotech drugs

By Bill Berkrot and Krista Hughes
NEW YORK/ATLANTA, Oct 5 (Reuters) - The Pacific trade deal
agreed on Monday, which grants biotechnology drug producers less
protection than offered by the United States, could put more
downward pressures on the costly drugs' pricing in the
industry's most lucrative market.
The United States and 11 trading partners, including Mexico,
Japan, Canada and Australia, wrapped up five years of talks
after securing a compromise on protection for biotech drugs that
would help determine when less expensive versions known as
biosimilars can enter the market. bought the
company in 2012 and has since seen billions of dollars in sales
for the drug. But Gilead may never have made the bet if it could
not enjoy a long enough period of protection, Brozak argues.
"The period of exclusivity draws the investors to these
companies," said Brozak. "You could see material harm to people
making investment decisions."

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.